Janssen Vaccines & Prevention B.V.
- Country
- 🇳🇱Netherlands
- Ownership
- -
- Established
- 2000-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.crucell.com
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
- Conditions
- Influenza Prevention
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 170
- Registration Number
- NCT05901636
- Locations
- 🇺🇸
Floridian Clinical Research LLC, Miami Lakes, Florida, United States
🇺🇸CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 132
- Registration Number
- NCT05327816
- Locations
- 🇺🇸
Floridian Clinical Research LLC, Miami Lakes, Florida, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States
🇺🇸Accel Research Sites, DeLand, Florida, United States
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Biological: Ad26.RSV.PreF-based Vaccine
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 755
- Registration Number
- NCT05101486
- Locations
- 🇺🇸
Clinical Research Consulting, Milford, Connecticut, United States
🇺🇸North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸Achieve Clinical Research, LLC, Vestavia Hills, Alabama, United States
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
- Conditions
- COVID-19 Prevention
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 861
- Registration Number
- NCT05091307
- Locations
- 🇺🇸
Wr McCr Llc, San Diego, California, United States
🇵🇱Synexus Polska Sp z o o Oddzial w Katowicach, Katowice, Poland
🇵🇱Synexus Polska Sp Z O O Oddzial W Lodzi, Lodz, Poland
A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Biological: Ad26.RSV.preF-based vaccine
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 250
- Registration Number
- NCT05083585
- Locations
- 🇺🇸
Accel Research Sites, Lakeland, Florida, United States
🇺🇸Progressive Medical Research, Port Orange, Florida, United States
🇺🇸Pharmax Research Clinic Inc, Miami, Florida, United States
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
- Conditions
- Influenza, Human PreventionRespiratory Syncytial Viruses Prevention
- Interventions
- Biological: Ad26.RSV.preF-based vaccineBiological: Quadrivalent High-dose Influenza VaccineBiological: Placebo
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 777
- Registration Number
- NCT05071313
- Locations
- 🇺🇸
Synexus Clinical Research US Inc, Saint Louis, Missouri, United States
🇺🇸Ark Clinical Research, Long Beach, California, United States
🇺🇸Research Centers of America, LLC, Hollywood, Florida, United States
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
- Conditions
- Respiratory Syncytial Virus Infection Prevention
- Interventions
- Other: PlaceboBiological: Ad26.RSV.preF-based Vaccine
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 1124
- Registration Number
- NCT05070546
- Locations
- 🇪🇸
Hosp Reina Sofia, Córdoba, Spain
🇪🇸Hosp Virgen de La Victoria, Málaga, Spain
🇺🇸Alliance for Multispeciality Research, Knoxville, Tennessee, United States
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
- Conditions
- Coronavirus Disease-2019 (COVID-19) Prevention
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 304
- Registration Number
- NCT05007080
- Locations
- 🇧🇷
Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP, Ribeirão Preto, Brazil
🇿🇦Setshaba Research Centre, Soshanguve, South Africa
🇦🇷CIPREC, Buenos Aires, Argentina
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 1541
- Registration Number
- NCT04999111
- Locations
- 🇺🇸
Central Phoenix Medical Clinic, Phoenix, Arizona, United States
🇺🇸Synexus Clinical Research US Inc, The Villages, Florida, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 1609
- Registration Number
- NCT04908722
- Locations
- 🇿🇦
Synexus Helderberg Clinical Research Centre, Cape Town, South Africa
🇿🇦Ndlovu Elandsdoorn Site, Dennilton, South Africa
🇿🇦Stanza Clinical Research Centre : Mamelodi, Mamelodi East, South Africa